A REPORT

ON
Industrial Tour
Submitted in Partial Fulfillment of the Requirements
for the Degree of

Bachelor of Pharmacy
by
NIDHI GUPTA
B. Pharm. IV Year, VIII Semester
(Roll no. 2000560500058)
Faculty of Pharmacy
BBDNIIT, Lucknow

to the
Faculty of Pharmacy
Dr. A. P. J. Abdul Kalam Technical University, Lucknow
(Formerly Uttar Pradesh Technical University, Lucknow)
2023-2024
 CERTIFICATE

This is to certify that NIDHI GUPTA (ROLLNO. 2000560500058) has carried out the
Industrial Tour for the award of Bachelor of Pharmacy from Dr. A.P.J. ABDUL
KALAM TECHNICAL UNIVERSITY, LUCKNOW under my supervision. This report
embodies result of original work and report are carried out by the student and the content
of the report do not form the basis for the award of any other degree to the candidate or to
anybody else from this or any other university/institution.

Dr. Shekhar Singh

Associate Professor

BBDNIIT, LUCKNOW

Date:
 DECLARATION

I hereby declare that the Industrial Tour mentioned in this report was carried out by me in
“CIPLA LIMITED”

Date: Nidhi Gupta

Roll No. 2000560500058

B.Pharm. IV Year, VIII semester,

BBDNIIT, LUCKNOW.
 ACKNOWLEDGEMENT

I sincerely appreciate the almighty God for his graces, strength, sustenance and above all, his
faithfulness and love from the beginning of my academic life up to this doctoral level. His
benevolence has made me excel and successful in all my academic pursuits.

I would like to express my indebtedness appreciation to my director Prof. (Dr.) Shailendra K.

Saraf, for his constant guidance and advice which played a vital role in making the execution
of the report possible. His kind suggestions were crucial making the report as flawless as
possible.

My unalloyed appreciation goes to my amiable, ever supportive and humble supervisor Dr.
Shekhar Singh, Associate Professor for his voluminous and invaluable contributions and
instructions throughout my studies. I hold your comments and encouraging words close to my
heart, they are more than light to my path. Your encouragement and high degree of freedom to
me in the course of this study is highly appreciated.

My profound thanks go to all classmates, especially to my friends and family for spending
their time in helping and giving support whenever I need it in fabricating my project.

Nidhi Gupta

B.pharm IV Year VIII semester

Roll No. 2000560500058

BBDNIIT, Lucknow
 TABLE OF CONTENT

S.NO CONTENTS PAGE NO.

1. Introduction 1-2

2. From Care to Cure and Logo 3

3. The One Cipla Credo 4

4. Board of Directors 5

5. Manufacturing 6

6. Introduction to Powders 7-10

7. Classification of Powders 11-12

8. Evaluation of Characteristics of Powders 13

9. Products 14-16

10. Innovations 17

11. Different Powdered Products Manufactured by Cipla 18

12. Different sites of Cipla Manufacturing Different 19-20

Powdered Products
13. Cipla Plant in Indore 21

14. Conclusion 22

15. References 23
 INTRODUCTION
At Cipla, they constantly work towards ensuring access to high quality and affordable
medicines to support patients in need. Which is why, they have been trusted by health care
professionals and patients across geographies for the last 8 decades.

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring for
Life has always been and continues to remain, our guiding purpose. Driven by the same
purpose, we have extended our presence to 80+ countries providing over 1,500 products
across various therapeutic categories in 50+ dosage forms. To make healthcare more
affordable globally, we are deepening our presence in the key markets of India, South Africa,
and U.S. among other economies of the emerging world.

Cipla has over 8 decades of caring for life.

1.1935-1960-Esteemed dignitaries visit CIPLA - Sardar Vallabhbhai Patel, Sushila Nayyar,

Shanti Swarup Bhatnagar, Ramaswamy Mudaliar, Amrit Kaur, Gulzarilal Nanda, Morarji
Desai, Sir C.V. Raman, Crown Prince Fazl of Saudi Arabia, Rafi Ahmed Kidwai, Mohd. Asaf
Ali and Maulana Azad.

2.1947-CIPLA celebrates India attaining Independence with flag hoisting ceremony at Mumbai
Central Headquarters.

3.1954- CIPLA exhibits at the All India Medical Conference.

4.1961-1975- (1968) CIPLA's turnover crosses the 1 crore mark.

5.1979-Installation of an ORG 2001 computer at Mumbai Central Headquarters to ease the

process of financial accounts and pay rolls, saving 20 days labour of seven persons.

6.1984-Inauguration of Patalganga manufacturing plant

7.1991-Cipla's turnover crosses Rs. 100 crores

8.2019-(a) Cipla USA furthers AMR stewardship with acquisition of key anti-infective
ZEMDRI™

Faculty of Pharmacy, BBDNIIT, Lucknow Page 1

(b) Cipla enters digital therapeutics by partnering with Wellthy Therapeutics in India and
Brandmed in South Africa to bring together behavioural science, real world clinical evidence
and artificial intelligence to provide real time monitoring, coaching and advice to patients.

9. 2020-(a) In continuance of its efforts to advance quality education and promote

industryacademia collaboration, Cipla Foundation, funds the set-up of a world class
chemistry research laboratory at the Indian Institute of Science Education and Research
(IISER) Pune.

(b) Cipla receives final approval for generic version of Proventil® HFA Inhalation Aerosol
(Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation).

(c) Cipla Foundation reaches out to local communities affected by Cyclone Amphan in West
Bengal, India by providing essential hygeine and food supplies to those in need.

(d) In June 2020, Cipla Foundation South Africa together with Miltons Matsemela hosted a
virtual Youth Day Run to raise funds for frontline COVID healthcare workers.

(e) Cipla signs a distribution agreement with Roche Products (India) Pvt. Ltd. to expand scope
of the partnership to include, marketing and distribution of Roche’s trademark oncology
drugs - Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova) in India.

(f) Cipla launches remdesivir under its brand name CIPREMI.

In May, Gilead Sciences Inc. extended a voluntary non-exclusive license to Cipla to

manufacture and market Cipla’s generic version of remedisvir called CIPREMI.

(g) Cipla and Boehringer Ingelheim forge partnership to co-market three oral anti-diabetic drugs
- Oboravo® (Empagliflozin), Oboravo Met® (Empagliflozin+Metformin) and Tiptengio®
(Empagliflozin+Linagliptin).

(h) Cipla is granted regulatory approval by the Drug Controller General of India (DCGI) for the
launch of Favipiravir in India under the brand name Ciplenza. Favipiravir is an off patent,
oral anti-viral drug that has been shown to hasten clinical recovery in COVID -19 patients
with mild to moderate symptoms.

(i) Cipla completes 85 years on 17th August

Faculty of Pharmacy, BBDNIIT, Lucknow Page 2

 From Care to Cure And Logo

With our growing scientific understanding of rare diseases, we shall continue to introduce
ground breaking therapies to give our patients their new beginnings!

1. Respiratory
2. API
3. HIV/AIDS
4. Oncology
5. Generic medicines
6. OTC
7. Diagnostics
8. Other Therapy
9. Covid Care

LOGO:

Faculty of Pharmacy, BBDNIIT, Lucknow Page 3

The OneCipla Credo
Our core values guide every conversation, organisational decision and anchor the actions of
our employees. We consistently revisit them and recalibrate strategies to stay ever-relevant to
our stakeholders.

Faculty of Pharmacy, BBDNIIT, Lucknow Page 4

 BOARD OF DIRECTORS

Dr. Y. K. Hamied (Non-Executive Chairman)

Mr. M. K. Hamied (Non-Executive Vice-Chairman)

Ms. Samina Hamied (Executive Vice-Chairperson)

Mr. Umang Vohra (Managing Director & Global Chief Executive Officer)

Mr. S. Radhakrishna (Non-Executive Director)

Mr. Ashok Sinha (Independent Non-Executive Director)

Mr. Adil Zainulbhai (Independent Non-Executive Director and Lead Independent Director)

Dr. Peter Mugyenyi (Independent Non-Executive Director)

Mr. P. R. Ramesh (Independent Non-Executive Director)

Ms. Punita Lal (Independent Non-Executive Director)

Mr. Robert Stewart (Independent Non-Executive Director)

Faculty of Pharmacy, BBDNIIT, Lucknow Page 5

 MANUFACTURING

Our investments in manufacturing capital include development of new drug delivery systems,
facilitation of infrastructure supporting API and formulation developments and strengthening
of platform technologies.

1. 32.72 Billion Tablets and Capsules

2. 144.20 Million Aerosol PMDIs
3. 11.45 Million Lyophilised injections
4. 750 Million Repsules
5. 50.60 Million Nasal Sprays
6. 51.20 Million Oral Liquid
7. 2.50 Million Ophthalmics

Faculty of Pharmacy, BBDNIIT, Lucknow Page 6

 INTRODUCTION TO POWDERS

POWDERS:
Powders are generally considered to be composed of solid particles of the same or different
chemical compositions having equivalent diameters less than 1000 micro meter.
However, the term 'powder' will also be used here to describe groups of particles formed into
granules which may have overall dimensions greater than 1000 /mi. The largest use of
powders pharmaceutically is to produce tablets and capsules. Together with mixing and
compression properties, the flowability of a powder is of critical importance in the production
of pharmaceutical dosage forms.

Pharmaceutical powders are solid dosage forms of medicament in which one or more drugs are
dispensed in finely divided state with or without excipients.

Advantages:

• It is used both internally and externally.

• It is more stable than liquid dosage form.
• It is convenient for the physician to prescribe a specific amount of powder.
• Onset of action is faster as compared to tablet, capsules because it is easily dissolved in
body fluids.
• Easy to carry.
• Easy to administration to the patient orally by dissolving in suitable liquids.

Faculty of Pharmacy, BBDNIIT, Lucknow Page 7

Disadvantages

• Drugs that have bitter taste, nausea and unpleasant taste cannot be administered
in powder form.
• Deliquescent and hygroscopic drugs cannot be dispensed in powder form they
are packed in double wrapping.
• Drugs which get affected by atmospheric condition are not suitable for dispense.
Method of preparation:

1. Reduction of particle size of all ingredients to the same range to prevent stratification
(separation of the large and small particles)
2. Sieving
3. Weighing each ingredient
4. Mixing
5. Packaging

NOTE: During powdering, weighing and mixing, there is loss of powder which cannot be
avoided. Therefore, while calculating the quantity of ingredients calculate for one extra
powder than required.

1. Size reduction
Is the process of reducing large solid units or substance into smaller unit mass, coarse
particles or fine particles. It is also termed comminution, grinding or pulverization.
Smaller particle size and increased surface area, leads to: Uniform distribution of the drug
substance in a powder mixture or solid dosage form to ensure dose to dose content
uniformity.

Size reduction on large scale

a .Compression: positive pressure, e.g., nut crusher, ball mill

b. impact: material is stationary and hit by an object ,e.g., hammer mill
c. Shear: cutting force, e.g., scissors, colloid mill
d.Attrition: breaking the edges of the solid either by impact or particle collisions (fluid energy
mill and roller mill).
2. Sieving

3. Weighing each ingredient

4. Mixing of powders

• The powders may be mixed by any one of the following methods:

 Spatulation
 Trituration

 Geometric dilution

Faculty of Pharmacy, BBDNIIT, Lucknow Page 8

  Sifting
 Tumbling

 Spatulation:

• In this method, the mixing of powders is done by the

movement of a spatula throughout the powders on a sheet
of a paper or on a porcelain tile. The method is very
useful in mixing:

a) Small amount of powder

b) Solid substances that liquefy or form eutectic mixtures, when in close and prolonged contact
with one another since very little compression or compact results. This method is not
suitable for large quantities of powders or for powders containing one or more potent
substances because homogenous blending may not occur.

Trituration:

• It is used both to reduce particle size and mix powders.

• If particle size reduction is desired along with mixing of

powders, a porcelain mortar with a rough inner surface is
preferred to a glass mortar with a smooth working surface. A
glass mortar may be preferred for chemicals that may strain a
porcelain surface and for simple mixture of substances without
special need for comminution. A glass mortar cleans more readily after use.

Geometric dilution:

• The method is used when potent substances are to mixed with a large amount of diluent. The
potent drug is placed upon an approximately equal amount of the dilute in a mortar and the
substances are slightly mixed by trituration. A second portion of diluent equal in volume to
the powder mixture in the mortar is added and trituration is repeated. The process is
continued, adding diluent equal in volume to the mixture in the mortar at each step, until all
the diluent is incorporated.

Faculty of Pharmacy, BBDNIIT, Lucknow Page 9

Sifting:

• The powders are mixed by passing through sifters. This process results in a light fluffy
product and is generally not acceptable incorporation of potent drugs into a diluent base.

Tumbling:

• It is the process of mixing powders in a large container rotated by an electronic rotated by

an electronic motor. These blenders are widely employed in industry as large volume
powder mixers.

Packaging:
• Powders may be wrapped in paper or dispensed in bulk powder in a wide mouth
container.
• Wrapping of powder – White glazed paper is generally used for wrapping. The wrapping
should be done on a clean tile or large sheet of a glazed paper to protect the product.

Faculty of Pharmacy, BBDNIIT, Lucknow Page 10

 CLASSIFICATION OF POWDERS
1. Bulk powder for internal use
2. Bulk powder for external use
3. Simple and compound powder for internal use
4. Powders enclosed in cachets and capsules
5. Compressed powders (tablets)
1. Bulk powder for internal use:
• Powders are dispensed in bulk, when accuracy of dosage is not important. Bulk powder
contains several doses of powder. They are supplied in wide mouthed containers that permits
easy removal of a spoonful of powder. The non potent substances which are supplied in bulk
are antacids and laxatives etc.

2. Bulk powders for external use:

Bulk powders meant for external use are non potent substances. These powders are supplied
in cardboard, glass or plastic containers, which are often designed for the specific method of
application. The dusting powders are preferably supplied in perforated or sifter top
containers.

The container should bear a label indicating that the powder is meant for external application.

The bulk powders which are commonly used for external application are as follows:
Dusting powders
Insufflations
Snuffs
Dentifrices
Dusting powders: These are meant for the external application to the skin and are generally
applied in a very fine state of subdivision to avoid local irritation. Hence, dusting powders
should be passed through seive no. 80 to enhance their effectiveness. Dusting powders are of
2 types:

 Medical
 Surgical

Medical dusting powders are used for superficial skin conditions, whereas surgical dusting
powder are used in body cavities and also on major wounds as a result of burns and umbilical
cords of infants.

• The dusting powders are dispensed in sifter or aerosol

containers.

• Dusting powders are generally non- toxic but inhalation of its

fine powdered ingredients by infants may lead to pulmonary
inflammation. So proper care should be taken while handling.
Use : Antiseptic, Astringent, Absorbent, Antiperspirant

Faculty of Pharmacy, BBDNIIT, Lucknow Page 11

3. Simple and compound powders for internal use:
• In this form of powder, each individual dose is enclosed in paper.

• The number of ingredient is one i.e. simple powder while more than one i.e. compound
powder.

• The minimum qty of each powder should not be less then 100 mg for it can be handled
conveniently by patient & can be weighed accurately.

Simple powder: In simple powder contains only one ingredient either in crystalline form or
amorphous form. If powder present in crystalline form then it is reduced to fine powder,
weighed the powder & divided into number of doses & wrapped as individual dose.

Compound powders: contains two or more than two substances which are mixed together.
Then divided into desired number of individual doses which are dispensed into each powder
paper.

4. Powders Enclosed in cachets:

• Cachets are solid dosage form of drug & cachets are also called as wafer capsules.

• These are moulded from rice paper, which is made by pouring a mixture of rice flour and
water between two hot, polishes, revolving cylinders. The water evaporates and a sheet of
wafer is formed.

• They are quite hard to swallow as such but they are softened by dipping in water for a few
seconds and then placed on the tongue and swallowed with a draught of water. After
swallowing cachet gets disintegrate and drug is released.

5. Compressed moulded tablets or tablet triturates or tablets:

• These are powders moulded into tablets.

• They are flat, circular disc & usually contains potent drug which is mixed with lactose,
dextrose or some other diluents.

• The apparatus is made up of stainless steel or plastic. It consist of upper & lower perforated
plates which is having an exactly the same number of holes as that of number of pegs in a
lower plate.

• The lower plate also have two large pegs which ensure correct fitting of the plates.

• The moulds are available in several sizes having a capacity ranging from 30 to 250 mg.

• Generally 50 to 250 tablet triturates can be prepared at a time from a tablet triturate mould.

Faculty of Pharmacy, BBDNIIT, Lucknow Page 12

 EVALUATION OF CHARACTERISTICS OF POWDER:
➢ Particle size and shape determination
➢ Surface area
➢ Density
• Bulk density
• Tapped density
• Granular density
• Granule strength and friability
• Flow properties
• Angle of repose
• Percentage compressibility index
• Hausner’s ratio
• Moisture content

Flow properties of granules are determined by measuring three parameters:

▪ Angle of repose
▪ Percentage compressibility index
▪ Hausner’s ratio

Faculty of Pharmacy, BBDNIIT, Lucknow Page 13

 PRODUCTS

CIPLA GENERICS:

ANTACID
BRAND NAME MOLECULE DOSAGE
FORM
ACI FREE (REGULAR) SVARJIKSARA 2.90G + Powder
NIMBUKAMLAM 2.10G

ACIGENE GEL (MINT)170ml MAGNESIUM HYDROXIDE IP 200 MG + Suspension

SIMETHICONE 50 MG + DRIED AL.
HYDROXIDE IP 250 MG / 10ML
OXECAINE DRIED ALUMINIUM + HYDROXIDE Gel
(170ml) GEL IP 291 MG + MAGNESIUM
HYDROXIDE IP 98 MG + OXETACAINE
BP 10 MG

DIGUSIL MPS (MINT) DRIED ALUMINIUM HYDROXIDE GEL Syrup

I.P. 250MG + MAGNESIUM
HYDROXIDE IP 200MG +
SIMETHICONE IP 50MG
ANTI-ALLERGIC
BRAND NAME MOLECULE DOSAGE FORM
CETCIP CETRIZINE HYDROCHLORIDE IP Tablets

CETCIP CETRIZINE HCL BP 5 MG/5 ML Syrup

ANTIBIOTIC
BRAND NAME MOLECULE DOSAGE
FORM
TARIFLOX OZ OFLOXACIN 200MG + ORNIDAZOLE Tablets
500MG
AZOMYCIN 200 ORAL AZITHROMYCIN 200 MG PER 5 ML Suspension
SUSPN
CEPHADEX 250 CEPHALEXIN 250MG Capsules
CEFTAZ-1000MG CEFTAZIDIME 1 GM Injection
CEFRAX DS 30 ML CEFIXIME IP 50 MG Syrup
ANTIASTHMATIC
BRAND NAME MOLECULE DOSAGE FORM
DERICIP THEOPHYLLINE IP 23 MG Tablets
+ ETOPHYLLINE 77 MG

Faculty of Pharmacy, BBDNIIT, Lucknow Page 14

DOXOCIP DOXOFYLLINE 400 mg + Tablets
EXCIPIENTS Q.S.

PAIN AND FEVER

BRAND NAME MOLECULE DOSAGE
FORM
CIPMOL 650 PARACETAMOL IP 650MG Tablets

PARACIP PARACETAMOL SYRUP 125MG/5ML Syrup

PARACIP PAIN RELIEF PARACETAMOL IP 500 MG + Tablets

TABS CAFFEINE ANHYDROUS IP 50 MG

PARACIP SUSP 250MG PARACETAMOL IP 250MG Suspension

CIPDOXIVID- LB CAPS DOXYCYCLINE HYDROCHLORIDE 100 Capsules

MG + LACTIC ACID BACILLUS 5
BILLION SPORES

ANTI-EMETIC
BRAND NAME MOLECULE DOSAGE FORM

VOMISTOP 10 DT DOMPERIDONE IP 10MG Tablets

DISPERSIBLE

VOMISTOP 30 ML DOMPERIDONE 1MG Suspension

VERTIGIL CINNARIZINE IP 20MG + Tablets
DOMPERIDONE
MALEATE IP 15MG
ANTI-DIARRHOEALS
BRAND NAME MOLECULE DOSAGE FORM

POWERGYL 30 ML OFLOXACIN 50 MG/5ML + Suspensions

METRONIDAZOLE BENZOATE
100 MG/5 ML

ROKO LOPERAMIDE HCL IP 2MG Capsules

VITAMINS
BRAND NAME MOLECULE DOSAGE
FORM
VITAFOL FOLIC ACID IP 5MG Tablets

CIPCAL D3 CHOLECALCIFEROL IP 60, 000 IU + EXCIPIENTS Sachet

Faculty of Pharmacy, BBDNIIT, Lucknow Page 15

 Q.S

EMRICH MULTI VITAMIN Capsules

FERICIP XT EACH 5 ML CONTAINS FERROUS ASCORBATE Suspension
ELEMENTAL IRON 30MG + FOLIC ACID IP
500MCG
CIPCAL SYRUP ELEMENTAL CALCIUM 250ML + VIT D3 125 IU Syrup

OTC- CIPLA HEALTH

BRANDS:

Nicotex ,ActivKids,Cofsils ,MamaXpert, Prolyte ORS ,UnoBiotics ,Maxirich Nicogum

Faculty of Pharmacy, BBDNIIT, Lucknow Page 16

 INNOVATIONS

Laboratory Information Management System (LIMS): We introduced automation in lab

operations to better control, manage, organize and document data in labs. This has resulted in
improvement in efficiencies by providing more analytical results at lower cost, enhancing
customer service, and reducing cycle time. It also ensured accuracy of results and more
effective use of resources.

Electronic Lab Notebooks (ELN): This system has been implemented to capture data during
research and track product development phases by automating the documentation process.
ELN has enabled the company to transit towards paperless R&D. It has also helped in
improving productivity by facilitating collaboration, sharing of information, and improving
accuracy and precision of research.

Closed Loop Marketing System: This solutions has enabled Cipla’s sales force to have a
meaningful discussion within the short facetime with the doctor. The CLM system
automatically analyses a physician’s preferences and arms the sales person to deliver
personalised content that closely matches the physician’s interests. The accompanying
edetailing software displays and manages visual aids such as presentations, reprints, and even
animations. As it does so, it captures the interactions between reps and physicians by
recording which items are viewed and for how long. The software also automatically
calculates expenses borne by the employee during his visits.

Manufacturing Execution Systems (MES): This solution helps achieve replicated

manufacturing processes and provides real-time feedback on any changes in requirements. It
automates material flow, accurately captures cost-information, and ensures paperless
workflow, thereby reducing waste, re-work and scrap. The captured data is used to generate
electronic batch records, historic references for long-term collection, and storage of
production information.

We are in the process of implementing Robotic Process Automation (RPA) for financial
operations in the accounts payable area and tax declaration with zero documentation. This
will allow us to efficiently process an estimated 20,000 invoices per month.

Faculty of Pharmacy, BBDNIIT, Lucknow Page 17

DIFFERENT POWDERED PRODUCTS MANUFACTURED BY CIPLA
 Fosmomycin trometamol powder
 Oral rehydration salts (ORS) Powder
 Clocip Antifungal powder
 Mamaxpert baby powder
 Salmeterol and fluticasone propionate powder

Faculty of Pharmacy, BBDNIIT, Lucknow Page 18

DIFFERENT SITES OF CIPLA MANUFACTURING DIFFERENT
POWDERED PRODUCTS
Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80
countries.

➢ ORS Powder:

Product description: It is used to replace fluids and Minerals (such as sodium, potassium) lost
due to diarrhea and vomiting. It helps to prevent or treat the loss of too much body water(
dehydration).

Manufactured by: Halewood laboratories Pvt.Ltd.319,Phase II,GIDC, Vatwa,

Ahmedabad,Gujarat.

➢ Fosirol :

Product description: It has in vitro activity against a broad range of gram positive and gram
negative aerobic microorganisms which are associated with uncomplicated urinary tract

infections.

Manufactured by: CIPLA LTD. Plot 9 &10,Indore,SEZ, Pithampur, MP

➢ Clocip:
Product description: It is helpful in treating fungal infections like athlete’s foot, ringworm,
Jack itch, and other skin infections.

Faculty of Pharmacy, BBDNIIT, Lucknow Page 19

Manufactured by: khushboo beauty care, survey no:- 69/4/2, village, Athal, Silvassa- 396230
(DNH)

➢ Mamaxpert:

Product description: It is a talc- free, dermatologically tested formula designed to pamper &
protect your baby's delicate skin.

Manufactured by: khushboo beauty care, survey no:- 69/4/2, village, Athal, Silvassa- 396230
(DNH)

➢ Seroflo rotacaps:

Product description: It is combination of two medicines that opens the airways & makes it
easier to breathe.

Manufactured by: CIPLA LTD. Plot 9 &10,Indore, SEZ, Pithampur, MP.

Faculty of Pharmacy, BBDNIIT, Lucknow Page 20

 CIPLA PLANT IN INDORE

Cipla’s Indore plant joins the World Economic Forum’s (WEF) prestigious Lighthouse
Network.

Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting
advanced fourth industrial revolution technologies to digitally transform operations

Demonstrates advanced technologies to drive productivity, workforce engagement,

sustainability, and resilience across 22 sites in parallel

Mumbai, India; October 11, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) (“Cipla”)
today announced that its Indore Oral Solid Dosage (OSD) plant has been designated by the
World Economic Forum as an ‘Advanced Fourth Industrial Revolution (4IR) Lighthouse’.
This is the first Cipla facility to receive the coveted recognition. The organisation is amongst
the first pharmaceutical companies in India & Asia and one of the few generic
pharmaceutical companies in the world to be part of the Global Lighthouse Network.

The Global Lighthouse Network is an exclusive community of manufacturing leaders from

across sectors who depict an accelerated adoption of 4IR technologies to transform factories,
value chains and business models for resilience, growth and sustainability.

Over the course of two years, Cipla deployed ‘Digital Automation Analytics’ (DAA) across a
network of 22 Indian sites in parallel to unlock end to end costs, productivity and quality
leadership. Cipla’s Indore Oral Solid Dosage (OSD) facility led this journey with 30+4IR use
cases, spanning Industrial Internet of Things, Digital, Advanced Analytics, Natural Language
Processing (NLP), Robotic Process Automation, etc. These revolutionary technologies (along
with other classic levers) resulted in reduced manufacturing cost, greater agility, and speed.
The impact generated across multiple fronts at Cipla’s Indore Oral Solid Dosage (OSD)
facility includes 23%* rise in productivity, 28% decrease in specific Greenhouse gas
(GHG)emissions and quality enhancement.

Faculty of Pharmacy, BBDNIIT, Lucknow Page 21

 CONCLUSION
While going through the virtual tour of this aforementioned industry, I came across the
aspects and analysis which are carried out in the industries and at the same time learnt about
vast varieties of products they manufacture. I also got to know about the rules & regulation
being followed in the industries like cGMP and GLP.

On visiting the websites, I got to know about the industry’s history, vision, mission, core
principles, research works, locations and their governing structure(by board of directors). It
was hence concluded that the work at top pharmaceuticals was properly organized, spaced
and well-illustrated.

The industries manufacture a no. of products including branded medicines, generics, OTC
medications, biologics including them in different dosage forms like tablets, capsules,
creams, gels, ointments, injections, suspensions, syrups, infusions, vaccines, etc. Furthermore
the numerous products were able to cover the different therapeutic areas and diseases
concerned.

The preparation of industrial report has been proven to be a golden opportunity in

understanding various operations involved in pharmaceutical industry.

Faculty of Pharmacy, BBDNIIT, Lucknow Page 22

 REFERENCES

Websites:
 https://www.cipla.com/home

Books:
 Aulton M.E ,Pharmaceutics,“The science of dosage form design”2nd edition,
published by Churchill Livingstone, Page no.-197

Faculty of Pharmacy, BBDNIIT, Lucknow Page 23